Praxis Precision Medicines (PRAX) to Release Quarterly Earnings on Monday

Praxis Precision Medicines (NASDAQ:PRAX) is expected to post its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to announce earnings of ($3.67) per share and revenue of $1.25 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Thursday, May 7th. The company reported ($3.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.38. On average, analysts expect Praxis Precision Medicines to post $-15 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Stock Performance

Shares of PRAX stock opened at $307.83 on Friday. The company has a market capitalization of $8.58 billion, a P/E ratio of -23.02 and a beta of 2.74. The company’s 50 day moving average price is $305.75 and its two-hundred day moving average price is $314.42. Praxis Precision Medicines has a 52 week low of $37.19 and a 52 week high of $366.52.

Insider Activity

In related news, Director Jill Desimone sold 11,600 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the sale, the director owned 2,337 shares in the company, valued at approximately $727,554.84. This represents a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PRAX. Amundi bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth approximately $233,000. MML Investors Services LLC acquired a new stake in shares of Praxis Precision Medicines in the 4th quarter valued at approximately $255,000. Ieq Capital LLC bought a new position in shares of Praxis Precision Medicines in the fourth quarter valued at $240,000. EntryPoint Capital LLC bought a new position in shares of Praxis Precision Medicines in the fourth quarter valued at $261,000. Finally, Russell Investments Group Ltd. increased its holdings in Praxis Precision Medicines by 1,668.7% during the third quarter. Russell Investments Group Ltd. now owns 4,404 shares of the company’s stock worth $233,000 after buying an additional 4,155 shares during the last quarter. 67.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PRAX has been the subject of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Praxis Precision Medicines in a report on Monday, July 13th. They issued a “buy” rating and a $447.00 price target for the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $374.00 price objective (down from $420.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. Piper Sandler reaffirmed an “overweight” rating on shares of Praxis Precision Medicines in a research report on Monday, July 13th. Needham & Company LLC upped their target price on shares of Praxis Precision Medicines from $537.00 to $575.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Praxis Precision Medicines in a report on Wednesday, May 27th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $563.50.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.